Olomoucine

• CAT Number: R003265
• CAS Number: 101622-51-9
• Molecular Formula: C15H18N6O
• Molecular Weight: 298.35
• Purity: ≥95%
• Synonyms: N2-[(2-Hydroxyethyl)-N6-benzyladenine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; NSC 666096
• Target: Cyclin-Dependent Kinases
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: 2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol
• InChI: InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20)
• InChIKey: GTVPOLSIJWJJNY-UHFFFAOYSA-N
• SMILES: CN1C=NC2=C1N=C(N=C2NCC3=CC=CC=C3)NCCO

Olomoucine is a CDK inhibitor that competes for the ATP binding site of the kinase. Olomoucine was shown to reversibly arrest differentiated Petunia cells induced to divide at G1 phase and cycling Arabidopsis cells in late G1 and G2.

Reference

1:Down-regulation of BNIP3 by olomoucine, a CDK inhibitor, reduces LPS- and NO-induced cell death in BV2 microglial cells. Tsou YC, Wang HH, Hsieh CC, Sun KH, Sun GH, Jhou RS, Lin TI, Lu SY, Liu HY, Tang SJ.Neurosci Lett. 2016 Aug 15;628:186-93. doi: 10.1016/j.neulet.2016.06.040. Epub 2016 Jun 21. PMID: 27345388 2:Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Hofman J, Kučera R, Neumanova Z, Klimes J, Ceckova M, Staud F.Xenobiotica. 2016;46(5):416-23. doi: 10.3109/00498254.2015.1086039. Epub 2015 Sep 12. PMID: 26364927 3:Synergistic actions of olomoucine and bone morphogenetic protein-4 in axonal repair after acute spinal cord contusion. Chen L, Li J, Wu L, Yang M, Gao F, Yuan L.Neural Regen Res. 2014 Oct 15;9(20):1830-8. doi: 10.4103/1673-5374.143431. PMID: 25422646 Free PMC Article4:Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. Cihalova D, Hofman J, Ceckova M, Staud F.PLoS One. 2013 Dec 23;8(12):e83467. doi: 10.1371/journal.pone.0083467. eCollection 2013. PMID: 24376706 Free PMC Article5:Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). Hofman J, Kučera R, Cihalova D, Klimes J, Ceckova M, Staud F.PLoS One. 2013 Oct 8;8(10):e75520. doi: 10.1371/journal.pone.0075520. eCollection 2013. PMID: 24116053 Free PMC Article6:Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, Staud F.Pharmacol Res. 2012 Mar;65(3):312-9. doi: 10.1016/j.phrs.2011.11.017. Epub 2011 Dec 6. PMID: 22173067 7:The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors. Korinkova G, Cwiertka K, Paprskarova M, Dzubak P, Hajduch M.Neoplasma. 2010;57(2):161-9. PMID: 20099981 8:The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B.Antivir Chem Chemother. 2010 Jan 5;20(3):133-42. doi: 10.3851/IMP1460. PMID: 20054100 Free PMC Article9:Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis. Małecki JM, Bentke A, Ostrowska B, Laidler P.Melanoma Res. 2010 Feb;20(1):52-8. doi: 10.1097/CMR.0b013e328332f1e6. PMID: 20010439 10:Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Wandl S, Wesierska-Gadek J.Ann N Y Acad Sci. 2009 Aug;1171:242-9. doi: 10.1111/j.1749-6632.2009.04700.x. PMID: 19723061